Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Manitoba

$32,822.00

Protective immune response against Nipah virus in swine

FY 2008-09

Summary
Nipah virus (NiV), a paramyxovirus emerged in Malaysia in 1998, caused an outbreak of severe encephalitis in man (mortality of 40%). Human infections in Malaysia were considered to be due to transmission of the virus from pigs. However recent outbreaks in Bangladesh, with 70% mortality, were associated with human-to-human spread of the virus. Nipah virus is on the list of possible bioterrorist agents, and is at this time classified as a biosafety level 4 (CL4) agent. due to its high virulence in humans, and absence of any vaccine or treatment. Long term objective of the proposed work is to gain better understanding of pathogenesis and protective immune response during NiV infection, facilitating development of vaccination strategy and antiviral treatment in swine, and subsequently in human. The proposed work would focus on development of vaccine strategy against NiV in pigs using canarypox virus based vaccine. Vaccines developed for the purpose of outbreak control are aimed on rapid onset of immunity, preventing spread of the virus. This strategy is especially pertinent to Canada, since NiV is not endemic to Americas, but could be introduced by accident or intentionally. Second vaccination strategy, for endemic areas, will aim at long term protection and disease control in swine. Vaccine, preventing spread of NiV to people, will be also of human health importance. Second component of the proposed research would investigate NiV interaction with the host interferon (IFN) system, and possible use of IFN as an antiviral for post-exposure and acute phase treament of the NiV infection. Although viruses use wide range of strategies to evade the antiviral effect of IFN-alpha/beta, based on knowledge of these strategies, effective treatment using IFN could be developed (e.g. as for hepatitis C).
Program
Discovery Grants Program - Individual
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
327187-2006
Name nom
Weingartl, Hana
Department département
Microbiology
Organization id
19
Institution établissement
University of Manitoba
Province en
Manitoba
Province fr
Manitoba
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2008
Competition year année de concours
2006
Award amount
32822
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1011
Committee name en
Integrative Animal Biology
Committee name fr
Biologie Animale Intégrative
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5202
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Virology
Research subject fr
Virologie
Partie
3
Nb partie
5
Application title
Protective immune response against Nipah virus in swine
Keyword
NA
Application summary
Nipah virus (NiV), a paramyxovirus emerged in Malaysia in 1998, caused an outbreak of severe encephalitis in man (mortality of 40%). Human infections in Malaysia were considered to be due to transmission of the virus from pigs. However recent outbreaks in Bangladesh, with 70% mortality, were associated with human-to-human spread of the virus. Nipah virus is on the list of possible bioterrorist agents, and is at this time classified as a biosafety level 4 (CL4) agent. due to its high virulence in humans, and absence of any vaccine or treatment. Long term objective of the proposed work is to gain better understanding of pathogenesis and protective immune response during NiV infection, facilitating development of vaccination strategy and antiviral treatment in swine, and subsequently in human. The proposed work would focus on development of vaccine strategy against NiV in pigs using canarypox virus based vaccine. Vaccines developed for the purpose of outbreak control are aimed on rapid onset of immunity, preventing spread of the virus. This strategy is especially pertinent to Canada, since NiV is not endemic to Americas, but could be introduced by accident or intentionally. Second vaccination strategy, for endemic areas, will aim at long term protection and disease control in swine. Vaccine, preventing spread of NiV to people, will be also of human health importance. Second component of the proposed research would investigate NiV interaction with the host interferon (IFN) system, and possible use of IFN as an antiviral for post-exposure and acute phase treament of the NiV infection. Although viruses use wide range of strategies to evade the antiviral effect of IFN-alpha/beta, based on knowledge of these strategies, effective treatment using IFN could be developed (e.g. as for hepatitis C).